Pharmacogenetic aspects in treatment of colorectal cancer--an update.

abstract：AIMS:The identification of predictive markers of response to chemoradiotherapy treatment remains a promising approach for patient management in order to obtain the best response with minor side effects. Initially, we investigated whether the analysis of several markers previously studied and others not yet evaluated co...

journal_title：Pharmacogenomics

authors： Balboa E,Duran G,Lamas MJ,Gomez-Caamaño A,Celeiro-Muñoz C,Lopez R,Carracedo A,Barros F

更新日期：2010-06-01 00:00:00

abstract：INTRODUCTION:Most cancer pharmacogenetic studies use germline DNA, as tumor tissue is often inaccessible in the advanced disease setting. However, this relies on the assumption that germline DNA is representative of the tumor genotype. To date, there has been little attention paid to defining the relationship between t...

journal_title：Pharmacogenomics

authors： Marsh S,Mallon MA,Goodfellow P,McLeod HL

更新日期：2005-12-01 00:00:00

abstract：:The most prescribed medication for controlling bronchoconstriction associated with asthma and chronic obstructive pulmonary disease are beta-agonists. The gene ADRbeta2 encodes the beta-2-adrenergic receptor and contains several common genetic variations that affect gene expression and receptor function in vitro. The ...

journal_title：Pharmacogenomics

authors： Hawkins GA,Weiss ST,Bleecker ER

更新日期：2008-03-01 00:00:00

abstract：:The multi-drug resistant transporter MDR1/P-glycoprotein, the gene product of MDR1, is a glycosylated membrane protein of 170 kDa, belonging to the ATP-binding cassette (ABC) superfamily of membrane transporters. MDR1 was originally isolated from resistant tumor cells as part of the mechanism of multi-drug resistance,...

journal_title：Pharmacogenomics

authors： Sakaeda T,Nakamura T,Okumura K

更新日期：2003-07-01 00:00:00

abstract：:Recent advances in next-generation sequencing techniques have greatly improved our understanding of the genomic alterations in bladder cancer. Cisplatin-based chemotherapy provides a viable treatment option in the neoadjuvant, adjuvant and metastatic setting in a selected group of patients, but chemoresistance is a ma...

journal_title：Pharmacogenomics

authors： Zuiverloon TC,Theodorescu D

更新日期：2017-08-01 00:00:00

abstract：AIM:Tamoxifen is one of the most commonly used endocrine therapeutic agents for breast cancer. Although many studies have examined whether the treatment outcomes of tamoxifen for breast cancer differ according to CYP2D6 genotype, the study results have been inconsistent, and the role of CYP2D6 in the prediction of pati...

journal_title：Pharmacogenomics

authors： Jung JA,Lim HS

更新日期：2014-01-01 00:00:00

abstract：:RNA splicing is a tightly regulated process. It is essential for gene expression and, therefore, intervenes in every biological phenomenon in mammals. RNA splicing regulation is cell type-specific in such a way that a cellular situation can be characterised by its repertoire of spliced events, the spliceome. Compariso...

journal_title：Pharmacogenomics

authors： Schweighoffer F,Ait-Ikhlef A,Resink AL,Brinkman B,Melle-Milovanovic D,Laurent-Puig P,Kearsey J,Bracco L

更新日期：2000-05-01 00:00:00

abstract：OBJECTIVES:In an attempt to elucidate the relationship between biomarkers of tumor hypoxia, glycolysis and angiogenesis, we tested the hypothesis that intratumoral gene expression of the hypoxia response (hypoxia inducible factor [HIF1 alpha and 2 alpha]), glycolysis (lactate dehydrogenase A [LDHA]), glucose metabolism...

journal_title：Pharmacogenomics

authors： Azuma M,Shi M,Danenberg KD,Gardner H,Barrett C,Jacques CJ,Sherod A,Iqbal S,El-Khoueiry A,Yang D,Zhang W,Danenberg PV,Lenz HJ

更新日期：2007-12-01 00:00:00

abstract：:A letter in response to: Andersson ML, Eliasson E, Lindh JD. A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele. Pharmacogenomics 13(7), 757-762 (2012). ...

journal_title：Pharmacogenomics

authors： Botton MR,Hutz MH,Suarez-Kurtz G

更新日期：2012-11-01 00:00:00

abstract：:Response to medication is highly variable, unpredictable and, at times, may be fatal. All drugs are more effective in certain groups of the population while showing no or minimal benefit in other groups. Although the current data on the subject are piecemeal, anecdotal evidence suggests that, in line with other common...

journal_title：Pharmacogenomics

authors： Rahmioğlu N,Ahmadi KR

更新日期：2010-02-01 00:00:00

abstract：:This narrative review describes implementation, current status and perspectives of a pharmacogenomic (PGx) program at the Brazilian National Cancer Institute (INCA), targeting the cancer chemotherapeutic drugs - fluoropyrimidines, irinotecan and thiopurines. This initiative, designed as a research project, was support...

journal_title：Pharmacogenomics

authors： Suarez-Kurtz G,Kovaleski G,Elias AB,Motta V,Wolch K,Emerenciano M,Mansur MB,Palladino AM,Accioly MT,Ferreira M,Gonçalves AA,de Melo AC

更新日期：2020-06-01 00:00:00

abstract：:In vitro human cell line models have been widely used for cancer pharmacogenomic studies to predict clinical response, to help generate pharmacogenomic hypothesis for further testing, and to help identify novel mechanisms associated with variation in drug response. Among cell line model systems, immortalized cell line...

journal_title：Pharmacogenomics

authors： Niu N,Wang L

更新日期：2015-01-01 00:00:00

abstract：:Quantitative trait analysis (QTA) can be used to test whether the expression of a particular gene significantly correlates with some ordinal variable. To limit the number of false discoveries in the gene list, a multivariate permutation test can also be performed. The purpose of this study is to identify peripheral bl...

journal_title：Pharmacogenomics

authors： Whistler T,Taylor R,Craddock RC,Broderick G,Klimas N,Unger ER

更新日期：2006-04-01 00:00:00

abstract：AIM:This study aimed to assess the effectiveness of genotype-guided warfarin dosing. PATIENTS & METHODS:A total of 109 adults were randomized to receive initial dosing as determined by an algorithm containing genetic (VKORC1 and CYP2C9) plus clinical information or only clinical information. Primary end points were th...

journal_title：Pharmacogenomics

authors： Jonas DE,Evans JP,McLeod HL,Brode S,Lange LA,Young ML,Shilliday BB,Bardsley MM,Swinton-Jenkins NJ,Weck KE

更新日期：2013-10-01 00:00:00

abstract：:Chronic fatigue syndrome (CFS) is prevalent, disabling and costly. Despite extensive literature describing the epidemiology and clinical aspects of CFS, it has been recalcitrant to diagnostic biomarker discovery and therapeutic intervention. This is due to the fact that CFS is a complex illness defined by self-reporte...

journal_title：Pharmacogenomics

authors： Vernon SD,Whistler T,Aslakson E,Rajeevan M,Reeves WC

更新日期：2006-03-01 00:00:00

abstract：AIMS:Survival and response rates in metastatic colorectal cancer remain poor, despite advances in drug development. There is increasing evidence to suggest that gender-specific differences may contribute to poor clinical outcome. We tested the hypothesis that genomic profiling of metastatic colorectal cancer is depende...

journal_title：Pharmacogenomics

authors： Gordon MA,Zhang W,Yang D,Iqbal S,El-Khouiery A,Nagashima F,Lurje G,Labonte M,Wilson P,Sherrod A,Ladner RD,Lenz HJ

更新日期：2011-01-01 00:00:00

abstract：:Carbamazepine (CBZ) is a common cause of life-threatening cutaneous adverse drug reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Previous studies have reported a strong association between the HLA genotype and CBZ-induced SJS/TEN. We investigated the association between the HLA g...

journal_title：Pharmacogenomics

authors： Yuliwulandari R,Kristin E,Prayuni K,Sachrowardi Q,Suyatna FD,Menaldi SL,Wichukchinda N,Mahasirimongkol S,Cavallari LH

更新日期：2017-12-01 00:00:00

abstract：:Atrial fibrillation (AF) is most common arrhythmia in general population, with increasing trend in mortality and morbidity. Electrophysiological and structural abnormalities, promoting abnormal impulse formation and propagation, lead to this disease. AF catheter ablation is related to a not small percentage of nonresp...

journal_title：Pharmacogenomics

authors： Sardu C,Santamaria M,Paolisso G,Marfella R

更新日期：2015-11-01 00:00:00

abstract：:Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...

journal_title：Pharmacogenomics

authors： Nickola TJ,Green JS,Harralson AF,O'Brien TJ

更新日期：2012-09-01 00:00:00

abstract：AIMS:To determine the extent of pharmacogenomics instruction at US and Canadian medical schools, characterize perceptions of curricular coverage, identify curricular resources and compare responses with similar studies conducted in US pharmacy schools and British medical schools. MATERIALS & METHODS:A survey was sent ...

journal_title：Pharmacogenomics

authors： Green JS,O'Brien TJ,Chiappinelli VA,Harralson AF

更新日期：2010-09-01 00:00:00

abstract：:miRNAs are reported to sequence-specifically control the translation of target mRNAs by binding to 3 UTRs. The abundant expression of miRNAs in the brain highlights their biological significance in neurodevelopment. Many studies have shown that miRNAs are involved in a variety of functions, including developmental tra...

journal_title：Pharmacogenomics

authors： Singh SK

更新日期：2007-08-01 00:00:00

abstract：AIMS:To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD). MATERIALS & METHODS:This was a multicenter prospective study. One hundred and forty four pa...

journal_title：Pharmacogenomics

authors： Tian J,Qin X,Fang K,Chen Q,Hou J,Li J,Yu W,Chen D,Hu Y,Li X

更新日期：2012-05-01 00:00:00

abstract：:The investigational drug dichloroacetate (DCA) is a metabolic regulator that has been successfully used to treat acquired and congenital metabolic diseases and, recently, solid tumors. Its clinical use has revealed challenges in selecting appropriate doses. Chronic administration of DCA leads to inhibition of DCA meta...

journal_title：Pharmacogenomics

authors： James MO,Stacpoole PW

更新日期：2016-05-01 00:00:00

abstract：:Genetic variation in the beta 2-adrenoceptor and its associated proteins is common and therefore potentially relevant to the clinician. Several functional SNPs have been described but in vitro studies have yielded inconsistent results. Confounding due to the variable presence of other polymorphic alleles may be the ex...

journal_title：Pharmacogenomics

authors： Taylor DR,Kennedy MA

更新日期：2002-03-01 00:00:00

abstract：:Liquid biopsy is a noninvasive dynamic approach for monitoring disease over time. It offers advantages including limited risks of blood sampling, opportunity for more frequent sampling, lower costs and theoretically non-biased sampling compared with tissue biopsy. There is a high degree of concordance between circulat...

journal_title：Pharmacogenomics

authors： Muluhngwi P,Valdes R Jr,Fernandez-Botran R,Burton E,Williams B,Linder MW

更新日期：2019-04-01 00:00:00

abstract：AIMS:Individuals with both diabetes mellitus (DM) and the Haptoglobin (Hp) 2-2 genotype are at increased risk of cardiovascular disease. As the antioxidant function of the Hp 2-2 protein is impaired, we sought to test the pharmacogenomic hypothesis that antioxidant vitamin E supplementation would provide cardiovascular...

journal_title：Pharmacogenomics

authors： Blum S,Vardi M,Brown JB,Russell A,Milman U,Shapira C,Levy NS,Miller-Lotan R,Asleh R,Levy AP

更新日期：2010-05-01 00:00:00

abstract：AIM:The activity of several key enzymes involved in the metabolism of many drugs is subject to change closely related to the age of patients. This possibility must also be considered in the case of tacrolimus, the most important calcineurins inhibitor, which is widely used in pediatric kidney transplantation. As well a...

journal_title：Pharmacogenomics

authors： Ferraresso M,Turolo S,Belingheri M,Tirelli AS,Cortinovis I,Milani S,Edefonti A,Ghio L

更新日期：2015-01-01 00:00:00

abstract：:Alteration in epigenetic regulation of gene expression is a frequent event in human cancer. CpG island hypermethylation and downregulation is observed for many genes involved in a diverse range of functions and pathways that become deregulated in cancer. Paradoxically, global hypomethylation is a hallmark of almost al...

journal_title：Pharmacogenomics

authors： Vucic EA,Brown CJ,Lam WL

更新日期：2008-02-01 00:00:00

abstract：:HER2 upregulation is related with poor outcome in many tumor types. Whereas anti-HER2 treatment is the standard approach as adjuvant therapy in HER2-overexpressing breast cancer, the frequent relapses reinforce the need for alternative treatments. Here we used next-generation sequencing (NGS) to evaluate miRNAs and ci...

journal_title：Pharmacogenomics

authors： Galli de Amorim M,Branco G,Valieris R,Tarcitano E,Tojal da Silva I,Ferreira de Araújo L,Noronha Nunes D,Dias-Neto E

更新日期：2019-05-01 00:00:00

abstract：:Aim: We investigated if DEPTOR polymorphisms influence metabolic parameters and risk for vascular complications in Type 2 diabetes (T2D) patients. Methods: T2D patients were genotyped for DEPTOR rs7840156, rs2271900 and rs4871827. We built low homology model of DEPTOR to check the position of two investigated substitu...

journal_title：Pharmacogenomics

authors： Klen J,Goričar K,Horvat S,Stojan J,Dolžan V

更新日期：2019-08-01 00:00:00